59 related articles for article (PubMed ID: 20301883)
21. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.
Tostes RC; Touyz RM; He G; Chen X; Schiffrin EL
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():25S-30S. PubMed ID: 12193048
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of plasma endothelin-1 concentration in tobacco smoking patients with essential hypertension].
Kosicka T; Kara-Perz H; Perz S
Przegl Lek; 2006; 63(10):957-9. PubMed ID: 17288193
[TBL] [Abstract][Full Text] [Related]
23. Are plasma renin activity and aldosterone levels useful as a screening test to differentiate between unilateral and bilateral renal artery stenosis in hypertensive patients?
Kotliar C; Inserra F; Forcada P; Cavanagh E; Obregon S; Navari C; Castellaro C; Sánchez R
J Hypertens; 2010 Mar; 28(3):594-601. PubMed ID: 20104188
[TBL] [Abstract][Full Text] [Related]
24. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
[TBL] [Abstract][Full Text] [Related]
25. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
Abecasis R; Kravetz D; Fassio E; Ameigeiras B; Garcia D; Isla R; Landeira G; Dominguez N; Romero G; Argonz J; Terg R
Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
[TBL] [Abstract][Full Text] [Related]
26. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
[TBL] [Abstract][Full Text] [Related]
27. [Role of renin-angiotensin-aldosterone system in pathogenesis of arterial hypertension in chronic renal failure].
Lifshits NL; Kutyrina IM
Ter Arkh; 1999; 71(6):64-7. PubMed ID: 10420461
[TBL] [Abstract][Full Text] [Related]
28. [Behavior of the plasma renin activity and aldosterone after salt restriction and upright posture in essential hypertension].
Kokot F; Kuska J; Chorqzy M
Z Gesamte Inn Med; 1976 Dec; 31(24):1016-20. PubMed ID: 1020406
[TBL] [Abstract][Full Text] [Related]
29. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
Feola M; Menardi E; Ribichini F; Vado A; Deorsola A; Ferrero V; Visconti G; Milanese U; Uslenghi E
Med Sci Monit; 2003 Aug; 9(8):CR341-5. PubMed ID: 12942029
[TBL] [Abstract][Full Text] [Related]
30. Endothelium and angiogenesis in white coat hypertension.
Karter Y; Aydin S; Curgunlu A; Uzun H; Ertürk N; Vehid S; Kutlu A; Simsek G; Yücel R; Arat A; Ozturk E; Erdine S
J Hum Hypertens; 2004 Nov; 18(11):809-14. PubMed ID: 15215878
[TBL] [Abstract][Full Text] [Related]
31. [Effect of Cholecalciferol and Diuretics as Components of Combination Antihypertensive Therapy on Plasma Renin Activity and Endothelial Function in Patients With Arterial Hypertension].
Yankouskaya VL; Snezhitskiy AV; Mamedov NM
Kardiologiia; 2017 Aug; 57(8):34-39. PubMed ID: 29041890
[TBL] [Abstract][Full Text] [Related]
32. Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone.
Falch DK; Schreiner AM
Acta Med Scand; 1981; 209(1-2):111-4. PubMed ID: 7010926
[No Abstract] [Full Text] [Related]
33. Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension.
Roos JC; Boer P; Peuker KH; Dorhout Mees EJ
Nephron; 1982; 32(3):209-13. PubMed ID: 7155242
[TBL] [Abstract][Full Text] [Related]
34. [Comparative study of anti-aldosterone agents and hypotensive diuretics in essential hypertension by a double blind test].
Shimizu N; Miyashita H; Koide K; Inoue N; Ogasawara M
Horumon To Rinsho; 1977 Feb; 25(2):167-74. PubMed ID: 322896
[No Abstract] [Full Text] [Related]
35. The effect of smoking on endothelin-1 in patients with chronic pancreatitis.
Śliwińska-Mossoń M; Milnerowicz S; Nabzdyk S; Kokot I; Nowak M; Milnerowicz H
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):288-96. PubMed ID: 25203431
[TBL] [Abstract][Full Text] [Related]
36. How effective is spironolactone for treating resistant hypertension?
Lyon C; Utter B; DeSanto K
J Fam Pract; 2019 Jun; 68(5):E11-E13. PubMed ID: 31287449
[No Abstract] [Full Text] [Related]
37. [PRELIMINARY NOTE ON THE TREATMENT OF ARTERIAL HYPERTENSION BY SPIRONOLACTONE ADMINISTRATION].
CHARMOT G; ANDRE LJ; LAFFITE A; BOUCHEAU P; LAGARDE B
Mars Med; 1964; 101():558-63. PubMed ID: 14177121
[No Abstract] [Full Text] [Related]
38. Moderate hypertension.
Lancet; 1985 Oct; 2(8461):948. PubMed ID: 2865442
[No Abstract] [Full Text] [Related]
39. [Not Available].
Zidek W
MMW Fortschr Med; 2023 Jan; 165(1):28. PubMed ID: 36648658
[No Abstract] [Full Text] [Related]
40. Treatments and diets associated with resistant arterial hypertension and their influence on the efficacy of spironolactone.
Quiñonez Quiñones NF; Santiago Ferrer JA; Burga Cisterna CA
Nefrologia (Engl Ed); 2024 Jun; ():. PubMed ID: 38906768
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
